✨ Free AI Report
Fulcrum Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Fulcrum Therapeutics, Inc.
Company Research

Fulcrum Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small molecules to improve the lives of patients with genetically defined diseases in areas of high unmet medical need. The company's lead ...

Analyst-debate audio for Fulcrum Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Fulcrum Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Fulcrum's pociredir is on track toward a 2026 registration-enabling trial with analyst price targets of $25, suggesting...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Rare Diseases & Hematology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 16, 2026
AI-Generated Research
30+ Page Report

Get the Latest Fulcrum Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Fulcrum Therapeutics, Inc. Overview

Pro stress-test →

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small molecules to improve the lives of patients with genetically defined diseases in areas of high unmet medical need. The company's lead candidate is pociredir, an oral small molecule designed to treat sickle cell disease and beta-thalassemia through fetal hemoglobin induction.

Strategic Profile

Pro stress-test →

Pociredir showed rapid, robust, clinically relevant response with mean fetal hemoglobin increasing 12.2% at Week 12, with 58% of patients achieving HbF levels ≥20% and 58% reporting zero vaso-occlusive crises. Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026, pending FDA feedback.

Competitive Landscape

Pro stress-test →

Pociredir faces competition from several approved therapies and ongoing clinical trials for sickle cell disease, including gene therapies and small molecule treatments. The company's proprietary EED inhibitor approach targeting fetal hemoglobin induction offers a differentiated oral mechanism compared to complex gene therapy alternatives.

Industry Context

Fulcrum Therapeutics, Inc. operates in Biopharmaceuticals - Rare Diseases & Hematology.

Key facts

Headquarters: Cambridge, Massachusetts, US · Market cap: $773M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Fulcrum Therapeutics, Inc..

  • Phase 1b PIONEER trial showed mean absolute HbF increased 12.2% (7.1% to 19.3%) at Week 12 with improvements in hemolysis markers and vaso-occlusive crisis reduction
  • Company has $352.3 million in cash as of December 31, 2025, with expected runway into 2029
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Announced positive 12-week Phase 1b PIONEER trial results with pociredir in sickle cell disease
  • December 2025Raised $164.2 million through underwritten public offering of common stock
  • +1 moreTrack every material event for Fulcrum Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Fulcrum Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Compare Fulcrum Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Fulcrum Therapeutics, Inc. operates in Biopharmaceuticals - Rare Diseases & Hematology. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Rare Diseases & Hematology research →
NEW · MCP server

Ask your AI assistant about Fulcrum Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Fulcrum Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Fulcrum Therapeutics, Inc. do this quarter?”
“Is Fulcrum Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Fulcrum Therapeutics, Inc. do?+
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small molecules to improve the lives of patients with genetically defined diseases in areas of high unmet medical need. The company's lead ...
What is Fulcrum Therapeutics, Inc.'s Cyborg Score?+
Fulcrum Therapeutics, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Fulcrum Therapeutics, Inc.'s main competitors?+
Named competitors include Gene Therapy Treatments, Approved SCD Therapies, Small Molecule Programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Fulcrum Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Fulcrum Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Fulcrum Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual